ITP Education Kit

Learn more about ITP and WinRho when you order the ITP Educational Resource Kit
educational patient kit

ITP Juego Educativo

Aprenda más acercade ITP
y WinRho cuando usted ordena el ITP Juego Educativo de Recurso

Patients and Caregivers

  • Welcome to WinRho.com

    This website is a resource for people seeking information about WinRho® SDF, a treatment option for Immune Thrombocytopenic Purpura (ITP) that may be helpful for you.

    Baxter's commitment to hematologic therapy continues with WinRho® SDF - the first Anti-D immunoglobulin treatment for Immune Thrombocytopenic Purpura or ITP.

    In studies of adult and pediatric ITP patients, WinRho demonstrates excellent efficacy and duration of response, with infusion times of only 3 to 5 minutes. 1,2

Indications and Usage1

WinRho® SDF must be administered via the intravenous route when used in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage in the treatment of non-splenectomized, Rho(D) positive:

  • children with chronic or acute ITP,
  • adults with chronic ITP, or
  • children and adults with ITP secondary to HIV infection

The safety and efficacy of WinRho® have not been evaluated in clinical
trials for patients with non-ITP causes of thrombocytopenia or in previously
splenectomized patients or in patients who are Rho(D) negative.

WinRho® SDF should not be administered to:

  • Rho(D) negative patients
  • splenectomized patients
  1. WinRho® SDF [Rho(D) Immune Globulin Intravenous (Human)] package insert, Cangene Corporation,Winnipeg, Canada. Baxter Healthcare Corporation, Westlake Village, CA, USA, April 2006.
  2. Data on file, Cangene Corporation, Baxter Healthcare Corporation.